The kidneys produce several hormones that regulate processes far beyond urine formation, including erythropoietin (which drives red blood cell production), renin (which controls blood pressure), and the active form of vitamin D (which governs calcium and bone health). They also contribute to less well-known signaling molecules like the anti-aging protein Klotho and thrombopoietin, which helps regulate platelets. Most people think of the kidneys purely as filters, but their endocrine role is so central to everyday physiology that when kidney function declines, the hormonal fallout can be as damaging as the waste buildup.
Erythropoietin and Red Blood Cell Production
Erythropoietin, usually shortened to EPO, is probably the kidney’s most famous hormonal product. Its job is straightforward: tell the bone marrow to make more red blood cells. What triggers this signal is a drop in oxygen delivery to kidney tissue. Specialized cells in the kidney’s outer region sense when oxygen levels fall and respond by ramping up EPO secretion. The hormone then travels through the bloodstream to the bone marrow, where it stimulates the production and maturation of red blood cells.
The sensing mechanism itself is elegant. Arterial blood arrives at the kidney, and the oxygen it carries gets translated into local oxygen tension in the tissue surrounding the kidney’s tubules. Cells in that region detect the resulting oxygen level and convert that information into a hormonal output, scaling EPO production up or down as needed.1Oxford Academic (Nephrology Dialysis Transplantation). Oxygen sensing in the kidney This is why people living at high altitudes naturally produce more EPO: thinner air means less oxygen reaching the kidneys, so the signal stays elevated.
EPO matters enormously in clinical medicine. In people with chronic kidney disease, the cells responsible for making EPO gradually lose their ability to function, leading to anemia that worsens quality of life and raises the risk of cardiovascular problems.2PubMed Central. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease For decades, the standard treatment has been injecting synthetic versions of EPO. More recently, a newer class of oral drugs works by mimicking mild oxygen deprivation, tricking the body into boosting its own EPO production rather than replacing it from outside.3PubMed Central. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors These drugs represent a shift in thinking from hormone replacement to hormone restoration.
Renin and Blood Pressure Control
Renin is an enzyme-hormone the kidneys release from tiny clusters of cells sitting at the tips of the small arteries that feed each kidney filtering unit. These cells, called juxtaglomerular cells, act as pressure sensors. When blood pressure drops or sodium delivery to the kidney falls, they release renin into the bloodstream.4PubMed Central. Renin Cells, From Vascular Development to Blood Pressure Sensing Three separate triggers govern renin release: nerve signals from the sympathetic nervous system, chemical messaging from a nearby cluster of cells called the macula densa, and the direct stretch of the arteriole wall itself, which functions like a built-in blood pressure gauge.
Once renin enters the blood, it kicks off a hormonal cascade called the renin-angiotensin-aldosterone system, or RAAS. Renin clips a liver-made protein called angiotensinogen to produce angiotensin I, which is then converted to angiotensin II by an enzyme in the lungs. Angiotensin II is a potent vasoconstrictor that raises blood pressure and also triggers the adrenal glands to release aldosterone, a hormone that tells the kidneys to hold onto sodium and water. The net effect is increased blood volume and higher pressure, restoring the conditions the juxtaglomerular cells were designed to maintain.5PubMed Central. A New Perspective on the Renin-Angiotensin System
This system is far from a one-way street. Researchers now recognize alternative pathways within RAAS that actually lower blood pressure and protect the heart, counterbalancing the classic pathway. Understanding these opposing arms is one reason the science of blood pressure regulation keeps getting more nuanced. From a practical standpoint, some of the most widely prescribed blood pressure medications, including ACE inhibitors and angiotensin receptor blockers, work by interrupting the RAAS cascade that the kidney’s renin sets in motion.
Activating Vitamin D
The kidneys do not produce vitamin D from scratch, but they perform the final and most critical step in turning it into a hormone the body can use. Vitamin D from sunlight or food first passes through the liver, where it becomes a storage form called 25-hydroxyvitamin D. That form is biologically inert. It has to travel to the kidneys, where an enzyme in the proximal tubules converts it into 1,25-dihydroxyvitamin D, commonly called calcitriol, the active hormone that regulates calcium absorption, bone mineralization, and immune function.6PubMed Central. Vitamin D and the kidney
This activation step is tightly controlled. A bone-derived hormone called FGF23 acts as a brake: when phosphate levels are adequate, FGF23 suppresses the kidney enzyme that activates vitamin D while simultaneously turning up the enzyme that breaks it down.7PubMed Central. FGF23 and Vitamin D Metabolism This creates a feedback loop involving bone, kidney, and the intestines. When the loop functions normally, calcium and phosphate stay balanced. When kidney function deteriorates, calcitriol production drops progressively, leading to poor calcium absorption, weakened bones, and a condition known as renal osteodystrophy.8PubMed Central. Effects of treatment of renal osteodystrophy on bone histology Replacing calcitriol in these patients helps, but it requires careful dosing because too much can push calcium levels dangerously high.
For people with healthy kidneys, the practical takeaway is that taking vitamin D supplements only works if your kidneys can complete that final conversion. This is why vitamin D supplements alone sometimes fail to raise active hormone levels in people with significant kidney impairment, even when blood tests show plenty of the storage form.
Klotho and Phosphate Balance
Klotho is a protein produced predominantly in the kidney’s tubule cells, and it has attracted intense scientific interest since the late 1990s because of its connection to aging. The Klotho gene encodes a protein that sits on cell surfaces and serves as a required co-receptor for FGF23, the bone-derived hormone that regulates phosphate and vitamin D. Without Klotho, FGF23 cannot properly signal the kidney to excrete phosphate or dial down vitamin D activation.9PubMed Central. Klotho and aging
What makes Klotho unusual is that it does double duty. Part of the protein gets clipped off and released into the bloodstream, where it circulates as a soluble factor with its own biological effects, including protecting cells and tissues from oxidative stress.10PubMed Central. Biological Role of Anti-aging Protein Klotho Animal studies have shown that mice engineered to lack Klotho develop a syndrome resembling accelerated aging: shortened lifespan, vascular calcification, bone loss, and skin atrophy. Mice engineered to overexpress it live longer than normal. Whether these findings translate cleanly to humans remains an open area of research, but the association between declining kidney Klotho production and the premature cardiovascular aging seen in kidney disease patients is one of the more provocative connections in nephrology.
Klotho’s role also ties the kidney directly into a bone-kidney feedback loop. Active vitamin D stimulates FGF23 release from bone. FGF23 then signals the kidney, through Klotho, to reduce phosphate reabsorption and scale back vitamin D activation. The kidney responds by adjusting how much phosphate it excretes and how much calcitriol it produces.11Springer Link. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis When kidney disease disrupts this axis, phosphate accumulates, vitamin D drops, and calcium gets pulled from bones and deposited in blood vessel walls. This is why kidney disease patients face such a high burden of cardiovascular disease.
Thrombopoietin
Thrombopoietin, or TPO, is the primary hormone that drives platelet production. The liver produces the majority of circulating TPO, but the kidneys contribute meaningfully. TPO is made continuously and cleared from the blood when platelets and their precursor cells bind to it, creating a simple feedback loop: more platelets in the blood means more TPO gets absorbed, so levels fall and production slows; fewer platelets means more free TPO, so the bone marrow gets a stronger signal to ramp up.12PubMed. Thrombopoietin (Mpl-ligand) and the regulation of platelet production
The kidney’s contribution to TPO becomes clinically relevant in kidney disease, where patients sometimes experience platelet abnormalities. It also matters after kidney transplantation, when restoring TPO production from the new kidney can improve platelet counts. Compared to EPO and renin, TPO from the kidney gets far less attention, partly because the liver dominates total production, but it is a genuine part of the kidney’s endocrine portfolio.
Medullipin and the Kidney’s Blood-Pressure-Lowering Side
Most discussions of kidney hormones and blood pressure focus on renin and its pressure-raising cascade. But the kidney also has a blood-pressure-lowering arm. Deep in the kidney’s inner medulla, specialized interstitial cells secrete a lipid substance called medullipin I. This precursor travels to the liver, where it gets converted by enzymes into its active form, medullipin II.13PubMed. Renal vasodepressor mechanisms: the medullipin system Medullipin II is a vasodilator that suppresses sympathetic nerve activity, promotes sodium and water excretion, and has a dampening effect on the central nervous system.14American Journal of Hypertension. The Medullipin System of Blood Pressure Control
The medullipin system is far less well known than RAAS, and research on it has been sporadic compared to the massive body of work on renin. But its existence is a useful reminder that the kidney does not just push blood pressure up. It maintains a balance between pressor and depressor signals, and damage to the kidney’s inner medulla may tip that balance toward sustained hypertension. Some researchers have speculated that this mechanism helps explain why certain forms of kidney damage produce high blood pressure even when renin levels look normal.
Prostaglandins and Other Local Signals
Beyond the hormones that enter the general circulation, the kidneys produce several signaling molecules that act locally. Prostaglandins are a good example. Kidney tissue synthesizes prostaglandins that dilate blood vessels within the kidney itself, helping to maintain blood flow under various conditions. In experimental settings, when the vasodilator bradykinin is infused into a kidney artery, renal blood flow initially rises and prostaglandin secretion increases.15American Journal of Physiology. Bradykinin-induced renal hemodynamic alterations: renin and prostaglandin relationships These locally produced prostaglandins interact with renin release, creating small feedback loops within the kidney that fine-tune blood flow and filtration on a moment-to-moment basis.
This local hormone production is one reason nonsteroidal anti-inflammatory drugs like ibuprofen can be hard on the kidneys. NSAIDs block prostaglandin synthesis throughout the body, but in the kidney, that blockade removes a protective vasodilatory signal, potentially reducing blood flow and causing fluid retention. For most healthy people, occasional use is fine, but in people with existing kidney disease or dehydration, the effect can be significant enough to cause acute kidney injury.
The Kidney as Hormone Clearinghouse
In addition to making hormones, the kidneys play a large role in removing them. Many hormones produced elsewhere are filtered, broken down, or cleared by the kidneys, so when kidney function fails, those hormones accumulate. Insulin is a notable example: the kidneys normally degrade a meaningful fraction of circulating insulin, which is why people with diabetes who develop advanced kidney disease often find that their insulin requirements drop unexpectedly. Several gut hormones involved in blood sugar regulation also pile up in kidney failure, contributing to the metabolic chaos that makes managing diabetes in advanced kidney disease so difficult.16Oxford Academic (Nephrology Dialysis Transplantation). Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients
This clearance function blurs the line between endocrine organ and metabolic gatekeeper. When doctors manage patients on dialysis, they have to account not just for the loss of kidney-produced hormones like EPO and calcitriol but also for the accumulation of hormones the kidneys would normally eliminate. The hormonal profile of someone with end-stage kidney disease looks dramatically different from a healthy person’s, and much of the difficulty in treating these patients comes from trying to compensate for a role that no dialysis machine can fully replicate.
Sex Hormones and How They Shape Kidney Endocrine Function
The kidney’s endocrine behavior is not identical in men and women. Estrogen and testosterone influence how the kidney expresses receptors for hormones like angiotensin II, the downstream product of renin. In animal studies, female kidneys show lower levels of angiotensin II receptor binding compared to males, and estrogen appears to actively suppress those receptors. When estrogen is removed surgically, receptor binding rises significantly; when estrogen is replaced, it drops back down.17PubMed. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats
This finding is part of a broader pattern that may help explain why premenopausal women tend to develop high blood pressure and kidney disease at lower rates than men of the same age. The protective effect of estrogen on kidney angiotensin receptors could be one piece of that puzzle. After menopause, when estrogen levels fall, women’s cardiovascular and kidney disease risk begins to converge with men’s. The research here is still largely based on animal models, and translating specific receptor-binding numbers to human clinical outcomes requires caution, but the direction of the evidence is consistent.
What Kidney Disease Does to the Hormonal Picture
Chronic kidney disease affects roughly one in ten adults worldwide, and its hormonal consequences start well before someone needs dialysis.3PubMed Central. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors EPO production declines, leading to anemia. Calcitriol drops, weakening bones and inviting calcium-phosphate imbalance. Klotho falls, removing a brake on vascular calcification. Renin regulation can become erratic, contributing to hypertension that further damages the kidneys in a vicious cycle. The medullipin system, already underappreciated, may lose its depressor influence. And the kidney’s hormone-clearance function deteriorates, letting insulin, gut hormones, and other signals accumulate to abnormal levels.
This cascade is why advanced kidney disease feels so systemic. It is not just a plumbing problem. Each lost endocrine function compounds the others: anemia worsens heart strain, bone disease leads to vascular calcification, and disrupted blood pressure control accelerates further kidney damage. Managing kidney disease increasingly means managing a web of hormonal deficits, and every replacement therapy, whether synthetic EPO, calcitriol supplements, or blood pressure medications targeting RAAS, is an attempt to patch one thread of that web at a time.
Circadian Rhythms in Kidney Hormone Release
The kidneys, like most organs, contain internal clocks that influence when and how much of each hormone gets released. Renin secretion, for instance, follows a daily rhythm, tending to peak during the night and early morning. This partly explains why blood pressure normally dips during sleep and rises after waking. EPO release also shows time-of-day variation, though it is primarily driven by oxygen levels rather than the clock itself. The interplay between circadian timing and the kidney’s hormonal output is an area of growing interest, particularly because disrupted circadian rhythms, as seen in shift workers or people with sleep disorders, may alter kidney hormone secretion in ways that raise long-term cardiovascular risk. Researchers are still mapping exactly how the kidney’s internal clock genes modulate each hormone, but the basic principle is established: the kidney does not operate at the same intensity around the clock.